{"id":762203,"date":"2025-09-09T22:36:02","date_gmt":"2025-09-09T22:36:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=762203"},"modified":"2025-09-09T22:36:02","modified_gmt":"2025-09-09T22:36:02","slug":"pd1-nsclc-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pd1-nsclc-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential_762203.html","title":{"rendered":"PD-1+ NSCLC Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/09\/1757426643.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"PD-1+ NSCLC Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/09\/1757426643.jpg\" alt=\"PD-1+ NSCLC Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2025<\/strong>&rdquo; report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the PD-1+ NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in the PD-1 Non-small cell lung cancer market.<\/p>\n<p style=\"text-align: justify;\"><strong>Discover the latest drugs and treatment options in the PD-1+ NSCLC Pipeline. Dive into DelveInsight&#8217;s comprehensive report today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">PD-1+ NSCLC Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the PD-1+ NSCLC Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><em>On 09 September 2025, OSE Immunotherapeutics<\/em><\/strong> announced a a phase 1\/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.<\/li>\n<li><strong><em>On 09 September 2025, Merck Sharp &amp; Dohme LLC<\/em><\/strong> conducted a study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902\/E7080) as first-line intervention in adults with metastatic nonsquamous non-small cell lung cancer.<\/li>\n<li>DelveInsight&rsquo;s PD-1+ NSCLC Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for PD-1+ NSCLC treatment.<\/li>\n<li>The leading PD-1+ NSCLC Companies such as <strong><em>Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma<\/em><\/strong> and others.<\/li>\n<li>Promising PD-1+ NSCLC Pipeline Therapies such as <strong><em>AZD2936, Cisplatin, Carboplatin, PF-06801591, AK112, Chidamide, Envafolimab<\/em><\/strong> and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Stay ahead with the most recent pipeline outlook for PD-1+ NSCLC. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">PD-1+ NSCLC Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>PD-1+ NSCLC Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Zimberelimab: Arcus Biosciences<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Zimberelimab is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lung cancer and classical Hodgkin&#8217;s lymphoma. Based on the results of a phase II trial, zimberelimab was recently approved for marketing in China as treatment for relapsed or refractory classical Hodgkin&#8217;s lymphoma. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit. The most advanced study with zimberelimab is in Phase III development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a\/A2b adenosine receptor antagonist in the clinic.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>PM8002: Biotheus<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">PM8002 is a bispecific antibody candidate with humanized anti-PD-L1 single heavy-chain variable (VHH) domains fused to an anti-VEGF-A IgG1 antibody containing Fc-silencing mutations. PM8002 had demonstrated a positive safety profile and encouraging antitumor activity presumably through reduced systemic toxicity by enriching anti-VEGF activity into the tumor microenvironment at ASCO Annual Meeting and ESMO Congress 2023. Currently, the drug is in Phase II\/III stage of its clinical trial for the treatment of NSCLC.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>RPH075: R-Pharm<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">R-Pharm&#8217;s pembrolizumab biosimilar, known as RPH 075, is a monoclonal antibody classified under antineoplastics, antivirals, and immunotherapies, specifically tumor-agnostic therapies. This biosimilar mimics the action of the originator drug, pembrolizumab, by targeting and antagonizing the programmed cell death 1 (PD-1) receptor on T lymphocytes. By blocking the interaction between PD-1 and its ligands, RPH 075 enhances T-cell mediated immune responses against cancer cells, promoting antibody-dependent cell cytotoxicity and providing a potent means to counteract tumors. Currently, the drug is in Phase I stage of its clinical trial for the treatment of NSCLC.<\/p>\n<p style=\"text-align: justify;\"><strong>The PD-1+ NSCLC Pipeline Report Provides Insights into<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of PD-1+ NSCLC with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1+ NSCLC Treatment.<\/li>\n<li>PD-1+ NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>PD-1+ NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD-1+ NSCLC market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Explore groundbreaking therapies and clinical trials in the PD-1+ NSCLC Marketed and Pipeline Drugs. Access DelveInsight&#8217;s detailed report now! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">New PD-1+ NSCLC Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>PD-1+ NSCLC Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma<\/em><\/strong> and others.<\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Oral<\/li>\n<li>Intramuscular<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>PD-1+ NSCLC Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal antibody<\/li>\n<li>Small molecule<\/li>\n<li>Peptide<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Unveil the future of PD-1+ NSCLC Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight&#8217;s expert analysis @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">PD-1+ NSCLC Market Drivers and Barriers<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the PD-1+ NSCLC Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>PD-1+ NSCLC Companies- <strong><em>Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma<\/em><\/strong> and others.<\/li>\n<li>PD-1+ NSCLC Pipeline Therapies- <strong><em>AZD2936, Cisplatin, Carboplatin, PF-06801591, AK112, Chidamide, Envafolimab <\/em><\/strong>and others.<\/li>\n<li>PD-1+ NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>PD-1+ NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Get the latest on PD-1+ NSCLC Therapies and clinical trials. Download DelveInsight&#8217;s in-depth pipeline report today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">PD-1+ NSCLC Companies, Key Products and Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) : Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Zimberelimab: Arcus Biosciences<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>RPH075: R-Pharm<\/li>\n<li>Preclinical Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) &#8211; Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) &#8211; Unmet Needs<\/li>\n<li>PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) &#8211; Market Drivers and Barriers<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pd1-nsclc-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pd1-nsclc-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2025&rdquo; report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pd1-nsclc-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential_762203.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,413],"tags":[],"class_list":["post-762203","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/762203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=762203"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/762203\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=762203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=762203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=762203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}